SOURCE: OmniComm Systems, Inc.

OmniComm Systems, Inc.

November 20, 2014 08:00 ET

Larix, Denmark's Full Service Contract Research Organization, Selects OmniComm's® TrialMaster® Electronic Data Capture Solution

FORT LAUDERDALE, FL--(Marketwired - Nov 20, 2014) - OmniComm Systems, Inc., (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, is pleased to announce that Larix; a full service Danish contract research organization (CRO) offering statistics, data management and medical writing, has selected TrialMaster electronic data capture (EDC) as its standard EDC technology. Located in the heart of the Denmark's Medicon Valley, one of Europe's preeminent centers for the life science industry, Larix's clinical development services are utilized by an ever increasing number of domestic and international organizations.

"As a leader in biometrics in the Nordic region we are aware that customers want and need the latest innovations that speed up studies, reduce costs and improve quality," said Klaus Juel Olsen, CEO, Larix. "With TrialMaster we can still deliver traditional studies but with the same system deliver innovations such as very fast SDTM data, powerful ad hoc reporting and targeted SDV with risk-based monitoring."

Larix selected TrialMaster EDC to support the business critical needs of their diverse client base that range from single compound biotechs to large pharmaceutical and medical device companies. OmniComm and Larix enjoy a long-standing strategic partnership that provides their clients with exceptional services and superior functionality. The release of TrialMaster 4.2 was a primary reason for Larix's decision. TrialMaster 4.2 includes over 300 new innovative productivity and functionality enhancements. TrialMaster's intuitive user interface and innovative data capture, data management and reporting functionality were significant factors in Larix's selection of TrialMaster. TrialMaster also includes embedded eLearning, enabling researchers to easily learn the system to quickly and accurately initiate new clinical trials. 

"OmniComm's continued growth strategy for the European market is led by innovation winning new business and strengthen relationships with existing customers," said Kuno van der Post, senior vice president of business development, OmniComm Systems, Inc. "TrialMaster 4.2 represents a significant advancement in EDC technology enabling organizations, like Larix, to achieve significant improvements in operational efficiency and productivity."

Supporting Information

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world's pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.

Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.